S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
NYSE:PKI

PerkinElmer - PKI Stock Forecast, Price & News

$160.96
+2.70 (+1.71%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$158.78
$163.93
50-Day Range
$132.37
$160.96
52-Week Range
$130.65
$203.16
Volume
1.85 million shs
Average Volume
825,692 shs
Market Capitalization
$20.30 billion
P/E Ratio
30.14
Dividend Yield
0.18%
Price Target
$161.13

PerkinElmer MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
0.1% Upside
$161.13 Price Target
Short Interest
Bearish
5.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.33mentions of PerkinElmer in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.08 M Sold Last Quarter
Proj. Earnings Growth
-15.58%
From $7.83 to $6.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Computer And Technology Sector

268th out of 658 stocks

Analytical Instruments Industry

10th out of 31 stocks

PKI stock logo

About PerkinElmer (NYSE:PKI) Stock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

PerkinElmer Price Performance

NYSE:PKI traded up $2.70 during trading hours on Thursday, hitting $160.96. 1,872,287 shares of the company's stock traded hands, compared to its average volume of 825,692. The firm has a market cap of $20.30 billion, a P/E ratio of 30.22, a P/E/G ratio of 0.42 and a beta of 1.12. PerkinElmer has a 52 week low of $130.65 and a 52 week high of $203.16. The business's fifty day simple moving average is $145.04 and its two-hundred day simple moving average is $158.71. The company has a quick ratio of 1.42, a current ratio of 2.02 and a debt-to-equity ratio of 0.63.

PerkinElmer (NYSE:PKI - Get Rating) last posted its quarterly earnings data on Monday, August 1st. The medical research company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.31. The company had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. PerkinElmer had a return on equity of 16.68% and a net margin of 13.21%. The firm's quarterly revenue was up .1% on a year-over-year basis. During the same quarter last year, the company earned $2.83 earnings per share. On average, research analysts anticipate that PerkinElmer will post 7.83 earnings per share for the current fiscal year.

PerkinElmer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Shareholders of record on Friday, October 21st will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.17%. The ex-dividend date of this dividend is Thursday, October 20th. PerkinElmer's dividend payout ratio (DPR) is currently 5.24%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. The Goldman Sachs Group decreased their price target on PerkinElmer from $200.00 to $175.00 and set a "neutral" rating for the company in a research report on Thursday, July 14th. Bank of America downgraded PerkinElmer from a "buy" rating to a "neutral" rating and set a $178.00 price target for the company. in a research report on Tuesday, August 2nd. Barclays raised their target price on PerkinElmer from $125.00 to $149.00 and gave the stock an "underweight" rating in a research report on Tuesday, August 2nd. Robert W. Baird lifted their price target on PerkinElmer from $198.00 to $202.00 and gave the company an "outperform" rating in a research report on Tuesday, August 2nd. Finally, UBS Group began coverage on PerkinElmer in a research report on Wednesday, July 20th. They issued a "buy" rating and a $160.00 price target for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $161.13.

Insiders Place Their Bets

In other PerkinElmer news, insider Andrew Okun sold 3,173 shares of PerkinElmer stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $165.42, for a total transaction of $524,877.66. Following the completion of the sale, the insider now owns 6,391 shares of the company's stock, valued at $1,057,199.22. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Andrew Okun sold 3,173 shares of PerkinElmer stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $165.42, for a total value of $524,877.66. Following the transaction, the insider now owns 6,391 shares in the company, valued at $1,057,199.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider James M. Mock sold 5,025 shares of PerkinElmer stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $145.49, for a total value of $731,087.25. Following the completion of the transaction, the insider now owns 27,577 shares in the company, valued at approximately $4,012,177.73. The disclosure for this sale can be found here. Insiders sold a total of 13,898 shares of company stock valued at $2,083,263 over the last 90 days. Insiders own 0.52% of the company's stock.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

PerkinElmer (NYSE:PKI) PT Raised to $202.00
Company News for Aug 2, 2022
PerkinElmer: Q2 Earnings Insights - Benzinga
See More Headlines
Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Company Calendar

Ex-Dividend for 8/12 Dividend
7/21/2022
Last Earnings
8/01/2022
Today
8/12/2022
Dividend Payable
8/12/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
71404610
Employees
16,700
Year Founded
1937

Price Target and Rating

Average Stock Price Forecast
$161.13
High Stock Price Forecast
$205.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$943.16 million
Pretax Margin
18.24%

Debt

Sales & Book Value

Annual Sales
$5.07 billion
Cash Flow
$14.53 per share
Book Value
$56.81 per share

Miscellaneous

Free Float
125,492,000
Market Cap
$20.30 billion
Optionable
Optionable
Beta
1.12

Social Links















PKI Stock - Frequently Asked Questions

Should I buy or sell PerkinElmer stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PKI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PKI, but not buy additional shares or sell existing shares.
View PKI analyst ratings
or view top-rated stocks.

What is PerkinElmer's stock price forecast for 2022?

7 brokers have issued 1 year target prices for PerkinElmer's stock. Their PKI share price forecasts range from $50.00 to $205.00. On average, they anticipate the company's share price to reach $161.13 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for PKI
or view top-rated stocks among Wall Street analysts.

How have PKI shares performed in 2022?

PerkinElmer's stock was trading at $201.06 on January 1st, 2022. Since then, PKI shares have decreased by 19.9% and is now trading at $160.96.
View the best growth stocks for 2022 here
.

When is PerkinElmer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PKI earnings forecast
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings data on Monday, August, 1st. The medical research company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.31. The medical research company earned $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. PerkinElmer had a net margin of 13.21% and a trailing twelve-month return on equity of 16.68%. The firm's quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.83 EPS.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Friday, July 22nd. Stockholders of record on Friday, October 21st will be given a dividend of $0.07 per share on Friday, November 11th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.17%. The ex-dividend date of this dividend is Thursday, October 20th.
Read our dividend analysis for PKI
.

Is PerkinElmer a good dividend stock?

PerkinElmer (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.18%. The dividend payout ratio is 5.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.24% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $1.40-$1.45 for the period, compared to the consensus estimate of $1.34. The company issued revenue guidance of $1.02 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pictet Asset Management SA (2.32%), Primecap Management Co. CA (1.07%), Robeco Schweiz AG (0.99%), King Luther Capital Management Corp (0.72%), Swiss National Bank (0.43%) and Sumitomo Mitsui Trust Holdings Inc. (0.39%). Insiders that own company stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Pascale Witz, Peter Barrett, Prahlad R Singh and Sylvie Gregoire.
View institutional ownership trends
.

How do I buy shares of PerkinElmer?

Shares of PKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $160.96.

How much money does PerkinElmer make?

PerkinElmer (NYSE:PKI) has a market capitalization of $20.30 billion and generates $5.07 billion in revenue each year. The medical research company earns $943.16 million in net income (profit) each year or $5.34 on an earnings per share basis.

How many employees does PerkinElmer have?

The company employs 16,700 workers across the globe.

Does PerkinElmer have any subsidiaries?

The following companies are subsidiares of PerkinElmer: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More

When was PerkinElmer founded?

PerkinElmer was founded in 1937.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.